Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $75,000.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the transaction, the insider owned 396,989 shares in the company, valued at approximately $9,924,725. The trade was a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Thursday, July 30th, Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.00, for a total value of $31,176.00.
• On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.00, for a total value of $10,714.00.
• On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00.
• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00.

Adaptive Biotechnologies Trading Up 1.1%

NASDAQ:ADPT opened at $24.74 on Friday. The firm has a market capitalization of $3.95 billion, a P/E ratio of -60.34 and a beta of 2.08. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The company has a fifty day moving average of $21.28 and a 200 day moving average of $17.12. Adaptive Biotechnologies Corporation has a 52 week low of $11.92 and a 52 week high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same period last year, the business earned ($0.17) EPS. Adaptive Biotechnologies’s revenue was up 21.5% on a year-over-year basis. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. TD Cowen upped their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. BTIG Research lifted their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Guggenheim boosted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Piper Sandler upped their target price on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus target price of $24.42.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Adaptive Biotechnologies in the 2nd quarter worth approximately $324,735,000. Ameriprise Financial Inc. boosted its position in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP purchased a new stake in Adaptive Biotechnologies in the fourth quarter worth $65,942,000. Finally, Geode Capital Management LLC grew its stake in Adaptive Biotechnologies by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after purchasing an additional 110,825 shares during the period. 99.17% of the stock is owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.